AVINEW NEO effervescent tablet for chickens

País: Irlanda

Língua: inglês

Origem: HPRA (Health Products Regulatory Authority)

Ingredientes ativos:

Live newcastle disease virus (VG/GA) component

Disponível em:

Merial Animal Health Limited

Código ATC:

QI01AD06

DCI (Denominação Comum Internacional):

Live newcastle disease virus (VG/GA) component

Dosagem:

5.5-7.0 log 10 50% embryo infective dose

Forma farmacêutica:

Effervescent tablet

Tipo de prescrição:

POM: Prescription Only Medicine as defined in relevant national legislation

Grupo terapêutico:

Chickens

Área terapêutica:

newcastle disease virus / paramyxovirus

Indicações terapêuticas:

Immunological - Live Vaccine

Status de autorização:

Authorised

Data de autorização:

2015-11-13

Características técnicas

SUMMARY OF PRODUCT CHARACTERISTICS
1 NAME OF THE VETERINARY MEDICINAL PRODUCT
AVINEW NEO effervescent tablet for chickens
2 QUALITATIVE AND QUANTITATIVE COMPOSITION
Each dose contains:
ACTIVE SUBSTANCE:
Live Newcastle disease virus, VG/GA-AVINEW strain
5.5 log
10
EID
50
(*)
(*) EID50: Egg Infective Dose 50 per cent.
EXCIPIENTS:
Brilliant blue FCF (E 133)
For the full list of excipients, see section 6.1.
3 PHARMACEUTICAL FORM
Effervescent tablet.
Blue mottled, round tablet.
4 CLINICAL PARTICULARS
4.1 TARGET SPECIES
Chickens (broiler, future layer and future breeder pullets).
4.2 INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES
In broiler chickens from the age of one day:
- Active immunisation against Newcastle disease to reduce mortality
and clinical signs associated with the disease.
Onset of immunity: 14 days after primary vaccination.
Duration of immunity induced by the vaccination scheme described under
section 4.9: protection until the age of 6
weeks.
In future layer and future breeder pullets from the age of 4 weeks:
- Priming for active immunisation against egg drop caused by Newcastle
disease before vaccination with an inactivated
vaccine (strain Ulster 2C) prior to the beginning of lay.
For duration of immunity of full schedule, see the leaflet of the
inactivated booster vaccine.
4.3 CONTRAINDICATIONS
None.
H
E
A
L
T
H
P
R
O
D
U
C
T
S
R
E
G
U
L
A
T
O
R
Y
A
U
T
H
O
R
I
T
Y
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
_D_
_a_
_t_
_e_
_ _
_P_
_r_
_i_
_n_
_t_
_e_
_d_
_ _
_0_
_6_
_/_
_1_
_0_
_/_
_2_
_0_
_1_
_6_
_C_
_R_
_N_
_ _
_7_
_0_
_2_
_4_
_8_
_9_
_8_
_p_
_a_
_g_
_e_
_ _
_n_
_u_
_m_
_b_